The estimated Net Worth of David A Giljohann is at least $822 Tisíc dollars as of 19 March 2019. David Giljohann owns over 7,000 units of Exicure Inc stock worth over $36,682 and over the last 6 years he sold XCUR stock worth over $0. In addition, he makes $785,462 as Chief Executive Officer, Interim Principal Financial Officer, Corporate Secretary a Director at Exicure Inc.
David has made over 1 trades of the Exicure Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 7,000 units of XCUR stock worth $16,800 on 19 March 2019.
The largest trade he's ever made was buying 7,000 units of Exicure Inc stock on 19 March 2019 worth over $16,800. On average, David trades about 1,400 units every 0 days since 2019. As of 19 March 2019 he still owns at least 23,666 units of Exicure Inc stock.
You can see the complete history of David Giljohann stock trades at the bottom of the page.
Dr. David A. Giljohann Ph.D. has been appointed as Chief Executive Officer, Interim Principal Financial Officer, Corporate Secretary, Director of the Company effective 9/30/2020. He has served as our Chief Executive Officer since November 2013 and as a member of our Board of Directors since March 2014. Dr. Giljohann was our founding scientist in 2011, served as our principal scientist from 2011 until June 2012, and served as our Chief Operating Officer from July 2012 to October 2013. Prior to joining us, Dr. Giljohann was the founding scientist of AuraSense, LLC, our largest stockholder, in 2009. Dr. Giljohann completed his Ph.D. in the laboratory of Dr. Mirkin where he developed oligonucleotide-modified nanoparticles, including NanoFlare™ and Spherical Nucleic Acid (SNA™) technologies. Dr. Giljohann was named to the Endpoint News’ “Under 40s” biopharma executives list in 2018 and the Analytical Scientist’s “Top 40 Under 40 Power List” in 2014. Dr. Giljohann has also been recognized for his work with a Materials Research Society Gold Award, Baxter Innovation Award, Rappaport Award for Research Excellence, NSEC Outstanding Research Award, and as a finalist in the National Inventors Hall of Fame Collegiate Inventors Competition. Dr. Giljohann received his B.A. in Biology and Ph.D. in Biochemistry from Northwestern University. Our Board believes that Dr. Giljohann’s experience in biotechnology research and development qualify him to serve on the Board.
As the Chief Executive Officer, Interim Principal Financial Officer, Corporate Secretary a Director of Exicure Inc, the total compensation of David Giljohann at Exicure Inc is $785,462. There are no executives at Exicure Inc getting paid more.
David Giljohann is 39, he's been the Chief Executive Officer, Interim Principal Financial Officer, Corporate Secretary a Director of Exicure Inc since 2020. There are 11 older and no younger executives at Exicure Inc. The oldest executive at Exicure Inc is David Walt, 67, who is the Independent Director.
David's mailing address filed with the SEC is C/O EXICURE, INC., 2430 N. HALSTED STREET, CHICAGO, IL, 60614.
Over the last 6 years, insiders at Exicure Inc have traded over $4,850,172 worth of Exicure Inc stock and bought 7,217,940 units worth $10,705,021 . The most active insiders traders include Timothy P Walbert, Co., Ltd. Dgp a Usa, Inc. Cbi. On average, Exicure Inc executives and independent directors trade stock every 90 days with the average trade being worth of $928,360. The most recent stock trade was executed by Co., Ltd. Dgp on 29 February 2024, trading 3,400,000 units of XCUR stock currently worth $4,488,000.
exicure, formerly aurasense therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. our 3-dimensional, spherical nucleic acid (sna™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. our lead programs address diseases from inflammatory disorders to oncology. sna constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. sna constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. moreover, snas can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
Exicure Inc executives and other stock owners filed with the SEC include: